DOI: https://doi.org/10.22141/2224-0721.15.5.2019.180039

The effectiveness of methylcobalamin in the complex treatment of diabetic peripheral neuropathy

L.K. Sokolova, Yu.B. Belchina, O.E. Ozeryanskaya, S.A. Chervyakova, M.D. Tronko

Abstract


Background. Diabetic neuropathy is the most common complication of diabetes mellitus (DM), found in 30–90 % of patients. The relevance of the study is due to the prevalence of diabetic neuropathy, as well as assessing the effectiveness of the use of methylated form of vitamin B12 in the treatment of patients with DM. The aim of this study was to determine the effectiveness of methylcobalamin (Diacobal, Kusum Pharm) in the complex treatment of patients with DM complicated by diabetic peripheral neuropathy (DPN). Materials and methods. The study was conducted by a simple open method. The Michigan Neuropathy Screening Instrument (MNSI), the Neurological Symptoms Score (NSS), the European Quality of Life Questionnaire (EQ-5D) were used to screen and determine the severity of symptoms of DPN. The neurological examination of patients included an assessment of various types of sensitivity (pain, tactile, vibrational, cold, heat, proprioceptive, pressure sensation). Blood levels of vitamin B12 (cyanocobalamin) were determined in all patients. Diacobal was added to the regimen of traditional treatment for DPN regardless of the levels of vitamin B12. Results. It was shown that DPN is a common complication of DM: according to subjective characteristics (MNSI and NSS scales), its symptoms were detected in 84.3 % of cases among DM patients. Subjective scales, such as EQ-5D, MNSI, NSS, are not enough to assess the presence and degree of polyneuropathy in DM patients. The data of these scales do not correlate with the results of a physical examination, but can be used as an auxiliary method for the analysis of subjective symptoms of a patient. A neurological examination is recommended for DM patients, regardless of whether they present active complaints. DPN was detected in 64.8 % of cases among diabetic patients according to objective criteria for the diagnosis and determination of various types of sensitivity (pain, tactile, vibrational, cold, thermal, proprioceptive, pressure sensation). Determining the level of cyanocobalamin should be used in conjunction with the determination of homocysteine and folic acid. Conclusions. The use of methylcobalamin (Diacobal in a daily dose of 1,500 μg for 3 months) in the complex treatment of diabetic neuropathy in diabetic patients is effective and safe, helps to eliminate the manifestations of diabetic neuropathy and improve the quality of life of patients.

Keywords


diabetes mellitus; diabetic peripheral neuropathy; vitamin B12; diagnosis; treatment

References


Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):31-8. doi: 10.2337/dc13-2114.

Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521-34. doi: 10.1016/S1474-4422(12)70065-0.

American Diabetes Association (ADA). Standards of medical care in diabetes - 2017. Diabetes Care. 2017;40(Suppl 1):S1-52.

Vinik AI. Clinical Practice. Diabetic sensory and motor neuropathy. N Engl J Med. 2016 Apr 14;374(15):1455-64. doi: 10.1056/NEJMcp1503948.

Zozulja IS., Zoulja AI, Volosovec' AO, Bigun IJu. Neuropathies: diagnosis, differential diagnosis, treatment. Ukrainian Medical Journal. 2019;2(1):37-39. (in Ukrainian).

Man’kovskii BN. Clinical manifestations and approaches to the treatment of peripheral sensorimotor diabetic neuropathy. Liky Ukrai'ny. 2009;2(128):63-66. (in Ukrainian).

Pankiv VI. Pathogenetic treatment of diabetic neuropathy: a comprehensive approach. Mìžnarodnij endokrinologìčnij žurnal. 2012;(47):55-60. (in Ukrainian).

Chopra K, Tiwari V. Alcoholic neuropathy: possible mechanisms and future treatment possibilities. Br J Clin Pharmacol. 2012 Mar;73(3):348-62. doi: 10.1111/j.1365-2125.2011.04111.x.

Levin OS. Polineiropatii: klinicheskoe rukovodstvo [Polyneuropathy: a clinical gide]. Moscow: MIA; 2005. 496 p. (in Russian).

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4.

Lutskii IS, Liutikova LV, Lutskii EI. B vitamins in neurological practice. Mìžnarodnij endokrinologìčnij žurnal. 2008;(21):89-93. (in Russian).

Allen LH. How common is vitamin В12 deficiency? Am J Clin Nutr. 2009 Feb;89(2):693S-6S. doi: 10.3945/ajcn.2008.26947A.

Nardin RA, Amic AN, Raynor EM. Vitamin B(12) and methylmalonic acid levels in patients presenting with polyneuropathy. Muscle Nerve. 2007 Oct;36(4):532-5. doi: 10.1002/mus.20845.

Candito M, Rivet R, Herbeth B, et al. Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study. Am J Med Genet A. 2008 May 1;146A(9):1128-33. doi: 10.1002/ajmg.a.32199.

Clarke R, Birks J, Nexo E, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr. 2007 Nov;86(5):1384-91. doi: 10.1093/ajcn/86.5.1384.

Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005 Jun;14(2):48-54.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта